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ARTICLE INFO                                         ABSTRACT 
 
 
 
 
Depression is a challenging condition to treat especially where the efficacy of the current types of 
treatments has been in debate for decades. The aim of this review was to compare the effectiveness of 
medications to psychotherapy interventions and the combination of both interventions in the treatment 
of depression. This was conducted by evaluating the evidence from studies that investigated the 
efficacy of alone interventions and dual therapy to identify the best course of treatment for depression. 
Twenty studies were selected of which ten were directly compared pharmacotherapy with 
psychotherapy and a further ten compared the combination of both to either of the two monotherapies. 
The results showed that in either of monotherapies cohorts, the rates of response, remission and 
changes in symptom severity were near equivalent for both but dropout rates were higher for the 
medications groups. Comparing dual therapy to the monotherapies showed higher efficacy in terms of 
response, remission and reduction of symptom severity for combination. The difference however seen 
less with pharmacotherapy and showed psychotherapy being least effective but the difference was in 
efficacy is small in the majority of the studies, to a point in which the question of‘is the difference 
clinically significant’ remained unanswered which require more definitive future research. 
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INTRODUCTION 
 
Depression is a prevalent mental health disorder, which is also 
one of the top causes of disability worldwide. Estimates of 
over 300 million people are affected by depression worldwide 
with women being the most affected when compared to 
men(World Health Organization, 2017). According to the 
Chief medical officer in the United Kingdom (UK) annual 
report in 2013 approximately 70 million sick days are 
accounted for due to mental illness which costs the UK 
economy between 70-100 billion pounds each year 
(Department of Health, 2014). In the 2013 UK Wellbeing 
Survey, nearly 1 in 5 people in the UK aged 16 and older 
showed symptoms of anxiety or depression. This percentage 
was higher for females (21.5%) than for males (14.8%), 
(Mentalhealth.org.uk, 2015).The evidence found shows that 
depression does not just affect a certain population as all ages 
and genders are affected by this crippling condition. However, 
depression prevalence is as high as 2 in 5 in older people living 
in care homes in the UK (Rcpsych.ac.uk, 2017). As a rule, 
psychotic diseases require pharmacological intervention as 
first line treatment with psychotherapy’s usefulness not 
exceeding an adjunct role, conversely in depression; 
psychotherapy provides an alternative first line treatment. The 
preferred treatment method usually dependent upon: treatment 
availability, previous history of response, patient preference 
and ability to comply with selected method (Bennett and 
Brown, 2003). 
 
In the 20th century Kraeplin identified the different causes of 
depression as being ‘endogenous’ and ‘exogenous’ (Sanders 
and Hill, 2014). This fundamental understanding helped in 
paving the way to more modern approaches to define 
depression. Kraeplin also introduced opium in the form of a 
tincture as treatment of melancholia or sadness. Modern 
medicines only started to peak after the 1950’s when 
antidepressants such as chlorpromazine were introduced. 
Opium use for depression was left behind after introduction of 
imipramine (Ban, 2002). 
 
The current knowledge for the pathophysiology of depression 
is conflicting, debatable and does not agree on a “unified 
hypothesis”(Hasler, 2010). This conflict is due to the fact that 
numerous theories are thought to be the trigger for depression 
but may not fully explain the aetiology of the disease. Genetic 
influence plays an undeniable role of the aetiology of 
depression (Brigitta, 2002). On a cellular level the alterations 
of serotonergic neuronal function in the CNS was recognised 
in patients diagnosed with depression (Owens, 1994). The 
observation of reduced platelet and brain serotonin transporter 
binding isbelieved to be consistent in patients diagnosed with 
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depression during the period of low mood. One of the most 
accepted theory’s is the ‘monoamine-deficiency’ hypothesis; 
which is explained by the inhibition of monoamine oxidase 
inducing a larger availability of monoamines in presynaptic 
neurones thus providing an antidepressant effect. This led to 
the belief that the depletion of neurotransmitters such as 
serotonin, dopamine or norepinephrine leads to depression 
(Hasler, 2010). 
 
There are a number of different types of antidepressant 
treatments available in the UK including selective serotonin 
reuptake inhibitors (SSRI), serotonin-noradrenaline reuptake 
inhibitors (SNRI) and tricyclic antidepressants (TCA) 
(NHS.UK, 2015). Cognitive behavioural therapy (CBT) can 
also be used as alternatives toor as a combination with 
antidepressants. According to NICE guidelines the number of 
CBT sessions can be classed as a low or high-intensity 
psychosocial intervention depending on how severe the patient 
symptoms are, e.g., for high intensity the number of sessions 
usually continue for up to 3-4 months and up to 16-20 sessions 
(Nice, 2016). 
 
The use of antidepressants reached its highest as the number of 
antidepressant items dispensed more than doubled in 10 years, 
were 64.7 million antidepressant items dispensed in 2016 
compared to 31.0 million dispensed in 2006 (Digital.NHS.uk, 
2017). NICE guidelines state that the use of psychotherapy or 
pharmacotherapy for depression is warranted and may be used 
depending on the severity of depression and the patient 
personal preference (NICE, 2016). 
 
A meta-analysis (Cuijpers et al., 2013) which compared the 
efficacy of mono-intervention of psychotherapy or 
pharmacotherapy stated that the difference in effects between 
the two was ‘small to non-existent’. Although it further states 
that different forms of both therapies have ‘varying degrees of 
efficacy’ in treating depression for example TCAs were less 
effective than psychotherapy and non-directive counselling 
was seen less efficacious than pharmacotherapy in general 
(Cuijpers et al., 2013). In another meta-analysis, both mono-
interventions (Leichsenring et al., 2016) were deemed to be 
equivalent in short term with more long-term benefit seen with 
psychotherapy. It further regards the limitations to response 
and remission in both interventions as a clear need for a more 
improved form of treatment. There seems to be a varying 
degree of agreeability in which intervention is better. A meta-
analysis (Kamenov et al., 2016) compared all three 
interventions showed that combination therapy is superior, 
however monotherapy with either intervention shown to be 
effective for improving function and QOL. Another study 
(Hollon et al., 2005) further clarifies that both mono-
intervention are effective but combination treatment may 
further enhance the likelihood of response over either 
monotherapy especially in severe depression. 
 
To assess depression, a depression rating scale is needed which 
is a useful way to determine patients level of depression before 
and after treatment to identify its success and effectiveness. It 
usually takes 15 minutes depending on the scale such as 
Hamilton Rating Scale for Depression (HRSD/HAM-D). 
Questions include feelings of guilt, presence of insomnia, 
displaying anxiety and/or somatic symptoms. Other forms of 
scales include Becks Depression Inventory, Montgomery-
Åsberg Depression Rating Scale (ADRS) and Children’s 
Depression Rating Scale-revised total score (CDRS) (Cusin et 
al., 2009). 
This systematic review will explore available evidence and 
compare the efficacy of various psychotherapeutic 
interventions with pharmacological intervention and their 
combination. 
 
The aim of this systematic review is to assess the effectiveness 
of antidepressant drugs in comparison to psychotherapy or a 
combination of both using randomised controlled trials where 
the efficacy of individual or combined therapies is the primary 
outcome. 
 
Methods and Design 
 
For the identification of trials comparing pharmacotherapy 
with psychotherapy or the combination of the two, three 
databases (PubMed, CENTRAL and Science Direct) were 
searched. The search strategy included the following 
keywords: Pharmacotherapy OR psychotherapy OR 
combination AND depression AND efficacy. 
 
Three hundred and eighty two trials were found in PUBMED, 
296 trials found in Cochrane Library and 2 trials found in 
Science direct databases (n=680). After reading the abstract 
660 papers were excluded as a result of either the abstract did 
not have relevant information to depression or free full text 
was not available, leaving 20 randomised controlled trials 
(RCT) which fit the inclusion criteria, with total of 3673 
patients. 
 
Tools used included the HRSD (n=16), Beck Depression 
Inventory (BDI) (n=1), CDRS revised total score (n=1) and 
Montgomery-Åsberg Depression Rating Scale (MADRS) 
(n=1).  Response and remission was recorded in some RCTs. 
 
Inclusion criteria: RCTs which 1) compared either 
psychotherapy intervention against any active pharmacological 
intervention OR the combination of both in the treatment of 2) 
depression 3) as the primary outcome of interest being the 
efficacy of the intervention (reduction in the depression 
symptoms severity) and participant’s attrition rate. 
 
For the purpose of this systematic review efficacy is defined as 
the response to treatment and reaching remission. 
 
Exclusion criteria: Current or past diagnosis of schizophrenia 
or other psychotic disorders; diagnosis of alcohol or drug 
abuse or dependence (except nicotine) or anorexia in the past 
year; psychotic symptoms, acute suicidal risks or the use of 
interventions such as ECT and cortical stimulation The 
Cochrane Bias risk tool was used to assess the validity and 
accuracy of the studies in terms of fairness and conducted 
appropriately (Methods.cochrane.org, 2017) 
 
Data extraction 
 
Outcomes of this study were assessed either as dichotomous 
variables (the proportion of patients who report improvement 
of depression symptoms, achieve remission and dropouts) or 
as continuous variables (depression severity scales). 
 
The primary outcome for this review was the efficacy of the 
used therapy described as the difference in mean depressive 
symptoms, as the included studies evaluated treatment efficacy 
on a wide range of scales. 
 
FINDINGS AND DISCUSSION 
 
The most commonly studied interventions were 
antidepressants, CBT or IPT. Firstly the efficacy of 
pharmacotherapy alone compared to the efficacy of 
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psychotherapy alone was compared, then the 
therapies were compared to the combination of 
pharmacotherapy and psychotherapy. 
 
Psychotherapy vs. Pharmacotherapy 
 
Ten RCTs were used to compare the efficacy of 
pharmacotherapy to that of psychotherapeutic treatment 
modalities. There were a total of 1602 patients included, of 
which 35.4% were male and included patients from the age of 
18 and above. The majority of the diagnosis was major 
depressive disorder (MDD) and the rest were dysthymia, 
Postpartum Depression (PPD), Treatment Refractory 
Depression (TRD) and atypical depression (Table 1).
studies used HDRS as a depression rating score apart from one 
(Leff et al.2000) which used BDI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rates of Response 
 
There were four studies that recorded response involving the 
mono therapies which was defined as a HDRS
lower or a 50% reduction HDRS score. Not every study made 
this aspect as an outcome which made the available data 
analysed limited, however from those studies which were 
analysed, the rate of response for both psychotherapy alone 
and pharmacology alone was similar with one of the studi
having identical rates of response at 58% 
2005). Rates of response can be linked to efficacy as it is a 
good sign of how effective the intervention is on patients. For 
studies which included more than one type of psychotherapy, 
the average mean was calculated and that result became the 
final result for figure 1 graph. The average rate of response for 
psychotherapy is 48.4% of the targeted population, which is of 
a similar value to pharmacotherapies mean rate of response of 
47.1%. The near equal rates of response can prove the efficacy 
of both interventions and the equivalence of them both.
 
Table1: Comparative analysis, efficacy of pharmacotherapy vs. psychotherapy
Study 
Numberof 
patients 
Intervention
(Barber et al., 
2011) 
156 
(MDD) 
SET (Psychotherapy)
Sertraline
(Pharmacotherapy)
(Elkin et al., 
1989) 
 
250 
(MDD) 
IPT (Psychotherapy)
CBT (Psychotherapy)
Imipramine (Pharmacotherapy)
(Leff et al., 
2000) 
 
77 
(MDD with a 
critical partner) 
Couples therapy (Psychotherapy)
Desipramine (Pharmacotherapy)
(David et al., 
2008) 
170 
(MDD) 
REBT (Psychotherapy)
CT (Psychotherapy)
Fluoxetine (Pharmacotherapy)
(Röhricht et al., 
2013) 
31 
(Chronic 
depression) 
Group BPT (Psychotherapy)
TAU (Pharmacotherapy)
(DeRubeis et al., 
2005) 
 
240 
(MDD) 
CT (Psychotherapy)
Paroxetine (Pharmacotherapy)
(Zlotnick, 2008) 
162 
(PPD) 
IPT (Psychotherapy)
Sertraline (Pharmacotherapy)
(Jarrett et al., 
1999) 
108 (atypical 
MDD) 
Acute phase CT (Psychotherapy)
Phenelzine (Pharmacotherapy)
(Miranda et al., 
2006) 
267 
(MDD) 
Group/individual CBT 
(Psychotherapy)
Paroxetine (Pharmacotherapy)
(Dekker et al., 
2008) 
141 
(MDD) 
SPSP (Psychotherapy)
Venlafaxine
(Pharmacotherapy)
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Figure 1 The average rates of response for psychotherapy and 
pharmacotherapy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rates of Remission 
 
Four studies were included in this analysis where remission 
was reported as primary outcome measures and from this we 
can see the results on the bar graph at figure 2. Similarly, there 
was no significant difference was calculated for remission, 
displaying a near equal efficacy. The mean number of patients 
achieved remission was 40.99% for psychotherapy and 
42.36% for pharmacotherapy respectively.
 
Figure 2 Rates of Remission for psychotherapy and pharmacotherapy
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(%) 
Dropouts 
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/ / 19 
/ / 32 
44.4 / 14 
41.6 / 25 
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/ / 32.2 
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Changes in depression scale 
 
Apart from Rohrichta et al.,(2013) the rest of the studies 
showed decreased depression severity regardless of the type of 
the intervention. The biggest decrease in depression severity 
was in Leff et al., (2000) in which the patients on av
symptoms reduction score of 16.4 in the psychotherapy 
treatment group on the DRS scores compared to a reduction of 
symptoms of 7.1 in pharmacotherapy treatment group. 
Coincidentally it was the only study that used BDI instead of 
HDRS. 
 
Rohrichta et al., (2013) reported that pharmacotherapy alone 
increased the severity of depression (+2.3 from baseline), the 
only study to have this finding. 
 
The other eight studies had more similarity
reduction in symptoms which was insignificant fo
interventions (Figure 3). Total average mean change in 
depression severity for psychotherapy was a decrease of 10.4 
and pharmacotherapy had a mean reduction by nine on the 
scale (difference of 1.4). 
 
 
Figure 3 Reduction in the depression symptoms for psychotherapy and 
pharmacotherapy 
Dropout Rate 
 
Figure 4 shows the dropout rate for the ten studies comparing 
pharmacotherapy with psychotherapy. From this graph we can 
see that nine out of the ten studies show that the dropout 
for pharmacotherapy was higher than psychotherapy. The 
biggest difference in dropout rate difference is Leff 
(2000) where 56.8% of patients taking desipramine dropped 
out compared to 15% withdrawing from psychotherapy. 
 
The most common reason for dropout in pharmacotherapy was 
side effects and the toll it was having on patients. Miranda 
Al., (2006) was the only RCT in which more patients from the 
psychotherapeutic intervention dropped out (64.5% vs 53%). 
 
 
Figure 4 Dropout rate for the ten studies comparing pharmacotherapy with 
psychotherapy 
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The calculated mean score of dropout rates for psychotherapy 
are 24.2% which is roughly a quarter of patients treated. The 
average number of patients to dropout for pharmacoth
was 33.53% or one in three patients.
 
Combination Therapy vs. Monotherapies
 
Ten RCTs were included in the findings of the efficacy of the 
combination of pharmacotherapy and psychological 
interventions compared with that of monotherapy of either 
intervention. A total of 2071 patients aged 11 and above were 
included in this analysis with the majority of the diagnoses 
being MDD, TRD and dysthymia. Some studies did not 
include response and/or remission as an outcome and therefore 
were not included the data analysis. Also, most studies used 
HDRS as a measurement of severity apart from three, two used 
CDRS-Rt and one used MADRS.
 
Rates of Response 
 
On figure 5, there seems to be a trend where combination 
achieves higher response rates than either interv
all apart from Markowitz et al
(2007), which has near equal rates of response for both 
pharmacotherapy alone and combination (58.3% vs 57.1% and 
39.4% vs 33.7% respectively). 
 
Studies with psychotherapy alone as a
significant difference in percentage of patients that have 
responded to the treatment compared to combination: Keller 
al., (2000) recorded as 48% vs 73%, Glass 
recorded as 43.2% vs 71% and Markowitz 
(2005)recorded as 32.9% vs 57.1% favouring combination. 
Pharmacotherapy has shown in three studies to have near equal 
or higher rates of response to combination therapy: Goodyer 
al., (2007) reported 39.4% vs 33.7% and Markowitz 
(2005) reported 58.3% vs 57.1%,Lam 
61% vs 63%, however the rest of the studies showed that 
combination was significantly superior to pharmacotherapy 
alone: Keller et al., (2000) reported 48% vs 73%, Schramm 
al., (2007) reported 51% vs 70%, Souza 
22.2% vs 35.5% and Glass et al
71%. Three studies compared all three interventions together; 
(Keller et al., (2000); Glass et al
(2005)), using these studies to compare efficacies s
the mean rate of response for psychotherapy was 41.36% 
whilst pharmacotherapy was 55.63%. However the 
intervention that proved most effective was combination 
therapy with 67.03%. Combining all studies, the averages can 
be shown from figure 5. Psychotherapy still has a mean rate of 
response of 41.36% as the other studies did not include data 
for this. For pharmacotherapy and combination, a further four 
studies were found matching the response rate. Considering 
the previous three studies mentioned t
for pharmacotherapy was 48.64% and 57.61% for combination 
therapy.  
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Figure 5 Rate of response, combination vs. either intervention
 
Rates of Remission 
 
The rates of remission are shown on figure 6. Combination 
therapy has the highest rate of remission in seven of the eight 
studies that recorded remission, the only study did not agree 
with this finding was Goodyer et al., (year) which reported 
21.3% vs 19.4%, in which the rates of remission were near 
equal but slightly higher for pharmacotherapy.
 
The remission rates for all psychotherapy interventions 
recorded were all very similar; 33% in Keller 
33.3% in Markowitz et al., (2005) and 32.1% in Jonghe 
(2004) with a mean of 32.8% of patients receiving treatment 
recovered. 
 
Two studies recorded the remission rates for all three 
interventions together; Keller et al., (2000) and Markowitz 
al., (2005). The mean rates of recovery were 33.15% for 
psychotherapy, 33.25% for pharmacotherapy and 50.45% for 
combination treatment. 
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(Schramm 
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(Goodyer et 
al., 2007) 
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(MDD) 
Fluoxetine (Pharmacotherapy)
Combination(+CBT)
(Glass, 
2005) 
439 (MDD) 
CBT (Psychotherapy)
Fluoxetine (Pharmacotherapy
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(Chaput et 
al. 2008) 
22 (MDD, 
TRD) 
CBT (Psychotherapy)
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Figure 6 Rates of Remission, combination vs. either intervention
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Five studies compared pharmacotherapy alone with 
combination, pharmacotherapy produced an average reduction 
of 10.06 through the five studies (-7.1,-4.5,
whereas combination managed to reduce the severity by 11
(-8.9,-5.8,-15.7,-16.2,-12.3). Psychotherapy interventions 
directly compared to combination therapy were limited to two 
studies. A mean reduction of 7.095 for psychotherapy (
7.4) and for combination therapy 8.02 (-8.64,
showed that combination therapy is slightly favoured to reduce 
more than mono therapy interventions (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Changes in depression scalefor combination vs. either intervention
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a mean of 29.76%, again showing that combination therapy is 
superior in adherence (20.2% vs 29.8%). 
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Limitations 
 
The limitations for this study include the fact that 
did not account for number of patients that responded or 
recovered due to treatment. The majority of studies did not 
compare three of the different active interventions between one 
another as it was more ‘combination vs one alone 
intervention’. This is due to the lack of studies found that 
included this, or if found, generally being available to 
subscribers of the journal/website. The limited amount of data 
found on ‘psychotherapy vs combination’ was due to again 
lack of RCTs reproducible or ca
were found showed that combination was considerably better. 
The DRS which had different forms didn’t allow some studies 
to be directly compared with the majority which were 
HDRS/HAM-D. 
 
CONCLUSION 
 
The results from the data synthesis section in this dissertation 
allowed a direct comparison between two interventions which 
are standard treatment for depression. Ten studies were found 
in which the efficacy of either monotherapy was compared. 
From rates of response and remission 
equally reduce depression severity in relatively equal amounts. 
The results from these studies showed that both interventions 
didn’t have any significant difference in response (48.4% vs 
47.1%) or remission (40.99% vs 42.36%). From the
measurements, it can be assumed that both interventions on 
their own are equal in efficacy. 
 
When reduction in depression severity is included which is 
change from baseline to endpoint on a DRS, both interventions 
manage to averagely decrease a sub
(difference of 1.4) favouring psychotherapy. Interestingly for 
Leff et al., (2000) there was a substantial difference in 
reduction (-16.4 vs -7.1) favouring psychotherapy, indicating 
at least for couples’ therapy that its effica
compared to antidepressants in patients who have depression 
and live with a critical partner. The difference in change of 
depression severity from baseline to endpoint varies from each 
study but this can be linked to time such as Dekker
(2008) in which the reduction was 
however this study only lasted eight weeks whereas Elkin 
al., (1989) lasted for double the amount of time and achieved a 
reduction of -12.2 (pharmacotherapy).
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account the patients involved TRDand that the 
pharmacological intervention was TAU (antidepressant regime 
in which the patients continued their on-going treatment and 
wasn’t monitored) whilst waiting for BPT after 12 weeks, this 
could lead to an increase in depressive symptoms with no 
change in treatment.  
 
Taken into account safety and dropout rates, psychotherapy is 
more superior to pharmacotherapy with less dropouts (24.2% 
vs 33.53%). The increase in dropouts in pharmacotherapy can 
be linked to the increased side effects displayed due to 
antidepressants including nausea and vomiting. As more 
patients have dropped out, this reduces the chance of achieving 
the end goal of remission and makes the intervention less 
efficacious. In Leff et al., (2000) there was a massive 
difference in dropouts (15% vs 56.8%) with more than half of 
patients taking antidepressants dropping out. This may be due 
to the fact that the depression was linked with a critical partner 
and discussing issues through counselling allows for a better 
understanding of the disease and both partners were involved 
allowing increased support at home increasing adherence. The 
only study in which psychotherapy caused more dropouts was 
in Miranda et al., (2006) controlled study in which 64.5% 
dropped out in psychotherapy compared to 53%. Both dropout 
rates are high however psychotherapy may have had more due 
to all patients being low-income minority women who may 
have had difficulty understanding English and making it to the 
selected appointments; which may have created a barrier 
between patient and psychotherapist leading to a lack of 
efficacy and eventually adherence. 
 
Throughout nearly all of the studies comparing psychotherapy 
and pharmacotherapy alone they were relatively equal in 
efficacy. 
 
A further ten studies were found directly comparing 
combination with either intervention alone. More studies were 
found comparing the effects of combination with 
pharmacotherapy than with psychotherapy, so more data is 
available for the prior. Six of the studies included 
psychotherapy and seven included pharmacotherapy 
comparisons. Three studies directly compared all three 
interventions and from this the rates of response are showed: 
41.36%, 55.63% and 67.03% with a trend that combination is 
superior to either intervention alone with psychotherapy being 
less efficacious. In only two studies (Markowitz et al., (2005) 
and Goodyer et al., (2007) did pharmacotherapy supersede 
combination and the response was near equal for both, the 
same cannot be said for psychotherapy which did significantly 
lower than both. The results here contrast from initial results 
comparing both monotherapies which showed that both 
interventions alone were equivalent in response.  
 
Remission again showed a trend in which combination was 
superior to both interventions alone with only one out of the 
eight studies having a lower recovery rate (Goodyer et al., 
(2007)) than pharmacotherapy and this was near equal. 
Goodyer et al., (2007) was measured using CDRS-Rtscore as 
the population was adolescents which brands ‘much improved’ 
as response rate and ‘very much improved’ as remission which 
is vague and isn’t as precise as HDRS. 
 
Only two studies (Keller et al., (2000)and Markowitz et al., 
(2005)) directly compared all three interventions remission 
rates and from this data, its shown that combination therapy 
has a much higher rate of recovery than either intervention 
alone with only a third recovering from either intervention 
alone whereas over half entered remission for dual 
therapy.This is somewhat parallel to primary results comparing 
either monotherapy in which both alone interventions caused 
near equal mean remission rates albeit lower.  
 
Concurring data from change in DRS showed that apart from 
Goodyer et al., (2007) and Chaput et al., (2008) all studies 
showed a larger decrease with combination therapy than any 
other intervention although some differences were small. 
Chaput et al., (2008) directly compared psychotherapy with 
combination and showed equal amounts of decrease in 
severity. The three studies that compared all three 
interventions together showed combination improves 
symptoms more than either intervention alone however in 
Markowitz et al., (2005) the difference in decrease is subtle (-
0.3) making it insignificant and near equal. Glass (2005) had 
the biggest decrease with combination therapy however 
CDRS-rt was used which has different values from HDRS. 
 
Disregarding these three studies and analysing the data for 
combination therapy vs pharmacotherapy showed a lower 
difference between the two but still favouring combination, 
similar results when comparing combination with 
psychotherapy alone where dual therapy has a slight advantage 
but small enough to question its clinical significance.  
 
The number of patients that dropped out didn’t seem to have a 
trend favouring combination unlike the other results collected 
however six of the possible ten studies had less dropouts 
occurring via combination therapy compared to either mono-
intervention. Interestingly Chaput et al., (2008) had the largest 
difference with over half of patients who were treated with 
CBT dropping out compared to less than a tenth with 
combination therapy. This could be due to the fact that these 
patients suffered from treatment-refractory depression 
indicating for patients with resistant depression, dual therapy 
of medication and psychotherapy is more effective in these 
patients. This theory can be proven further by Souza et al., 
(2016) which had one of the biggest dropout differences 
between combination and pharmacotherapy indicating better 
adherence with dual therapy, this study also concerned patients 
with TRD. Increased adherence leads to an increased chance of 
recovery which is shown in Souza et al., (2016) remission 
rates, however Chaput et al., (2008) did not disclose data for 
this and both therapies managed to decrease equal amount of 
severity as seen on figure 7.  
 
Considering the three studies that studied all three 
interventions, the attrition rate for the combination therapy is 
lower than individual therapies. From this direct comparison 
we can acknowledge that its more accepted and liked by 
patients than monotherapy. Pharmacotherapy did better than 
psychotherapy but worse than combination however with 
Chaput et al., (2008) high attrition rate for psychotherapy this 
may be a leading factor to a higher average. 
 
In conclusion when compared alone they have similar benefits 
in reducing the symptom severity, although pharmacotherapy 
may reduce it faster initially. The number of patients 
withdrawing increased more with pharmacotherapy due to 
mainly adverse events from the drug. The contrasting effect of 
psychotherapy being less effective than pharmacotherapy 
when compared with combination and each other indicates 
further research may be needed.  
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Combination therapy proved more efficacious in producing a 
response and remission; however, changes in HDRS remain 
similar to a degree, asking the question is the difference in 
effectiveness clinically important? From this review it shows 
that further research is needed for this question, but 
combination is more effective, although not appropriate for 
every population. From attrition rates it is shown that 
combination therapy has increased adherence compared to 
either intervention alone.  
 
Overall it can be said that combination is better than either 
intervention alone, but how much this affects the population, 
cost to the NHS and various other mitigating factors show that 
further research is needed. 
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